8-K: Passage Bio Regains Nasdaq Listing Compliance

Passage Bio, Inc. announced it has regained compliance with Nasdaq's minimum bid price requirement, resolving a previous listing deficiency.

Summary

• Passage Bio, Inc. received notice from Nasdaq on July 28, 2025, confirming compliance with Nasdaq Listing Rule 5450(a)(1).
• The company's common stock closing bid price had been at least $1.00 per share for at least 10 consecutive business days as of July 28, 2025.
• All other applicable criteria for continued listing on the Nasdaq Capital Market are satisfied.
• The listing matter is now closed.
• Previously, on August 1, 2024, the company received a notice of non-compliance because its common stock closing bid price had fallen below $1.00 per share for 30 consecutive business days.

Sentiment

Score: 8

Explanation: The sentiment is highly positive as the company has successfully resolved a critical listing compliance issue, removing a significant overhang and risk of delisting from Nasdaq.

Positives

• Regained compliance with Nasdaq's minimum bid price requirement, removing the risk of delisting.
• The listing matter with Nasdaq is officially closed, providing certainty regarding the company's exchange listing status.
• Satisfies all applicable criteria for continued listing on the Nasdaq Capital Market.

Negatives

• Previously failed to meet Nasdaq's minimum bid price requirement, leading to a non-compliance notice on August 1, 2024.

Risks

• The company previously faced the risk of delisting from the Nasdaq Global Select Market due to its common stock trading below the $1.00 minimum bid price requirement.

Future Outlook

The filing does not contain specific forward-looking statements or guidance beyond the resolution of the Nasdaq listing matter.

Industry Context

Maintaining Nasdaq listing is crucial for biotechnology companies like Passage Bio to ensure liquidity, access to capital markets, and investor visibility. Non-compliance with listing rules can deter institutional investors and impact a company's ability to raise funds. Regaining compliance aligns Passage Bio with industry peers that maintain standard exchange listings.

Comparison to Industry Standards

• Many small and mid-cap biotechnology companies face challenges in maintaining minimum bid price requirements, especially during periods of clinical trial setbacks or broader market downturns. Passage Bio's resolution of this issue brings its listing status in line with the majority of publicly traded biotech firms that successfully maintain their exchange listings.
• Comparable companies that have faced similar minimum bid price challenges and subsequently regained compliance include various small-cap biopharmaceutical firms, demonstrating that such events are not uncommon but require active management to resolve.

Stakeholder Impact

• Shareholders: The resolution of the listing deficiency removes the risk of delisting, which could have negatively impacted liquidity and investor confidence. This provides stability for current shareholders.
• Investors: Potential investors will view the company more favorably now that the listing risk has been mitigated, potentially increasing interest and investment.

Key Dates

Recommendation

The resolution of the Nasdaq listing compliance issue is a significant positive, removing a major overhang and risk of delisting. This stabilizes the company's market presence and access to capital. However, this development primarily addresses a compliance issue rather than a fundamental change in the company's core business operations or pipeline progress. While it removes a negative catalyst, it does not inherently create a new positive catalyst for significant upside. Therefore, a 'hold' recommendation is appropriate, acknowledging the improved stability while awaiting further operational or clinical developments.

Keywords

Nasdaq compliance, minimum bid price, listing requirements, Passage Bio, PASG, stock market, biotechnology, SEC filing, 8-K